Securian Asset Management Inc. Trims Stock Position in Solventum Corporation (NYSE:SOLV)

Securian Asset Management Inc. trimmed its position in Solventum Corporation (NYSE:SOLV) by 2.7% in the 1st quarter, Holdings Channel.com reports. The fund owned 7,174 shares of the company’s stock after selling 200 shares during the quarter. Securian Asset Management Inc.’s holdings in Solventum were worth $546,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in SOLV. Clarity Asset Management Inc. acquired a new stake in shares of Solventum in the 4th quarter worth $25,000. Rossby Financial LCC acquired a new stake in shares of Solventum in the first quarter valued at about $25,000. Raiffeisen Bank International AG acquired a new stake in shares of Solventum in the fourth quarter valued at about $29,000. Colonial Trust Co SC raised its position in Solventum by 240.7% during the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company’s stock worth $34,000 after acquiring an additional 361 shares during the last quarter. Finally, Hara Capital LLC acquired a new position in Solventum during the first quarter worth about $38,000.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $73.90 on Friday. The company has a current ratio of 1.19, a quick ratio of 0.85 and a debt-to-equity ratio of 2.40. The stock has a market capitalization of $12.79 billion, a P/E ratio of 34.21, a P/E/G ratio of 1.87 and a beta of 0.55. The business has a 50-day moving average price of $74.13 and a two-hundred day moving average price of $72.62. Solventum Corporation has a 1-year low of $52.40 and a 1-year high of $85.92.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.15. Solventum had a return on equity of 31.01% and a net margin of 4.55%. The firm had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. During the same quarter in the prior year, the firm posted $2.08 EPS. The business’s revenue was up 2.7% on a year-over-year basis. Equities analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on SOLV. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $80.00 to $103.00 in a report on Tuesday. Piper Sandler raised shares of Solventum from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $78.00 to $87.00 in a report on Monday, May 19th. KeyCorp assumed coverage on shares of Solventum in a research report on Friday, June 6th. They set a “sector weight” rating for the company. Finally, Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a research report on Tuesday, July 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Solventum currently has a consensus rating of “Hold” and a consensus price target of $84.38.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.